| 11666320 |
Fixation members, assemblies, and related systems and methods |
Samantha JOHNSON, Joseph Algeri, David B. Spenciner, Dennis E. Connelly, Reagan A. Theis |
2023-06-06 |
|
| 9765340 |
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders |
John M. Yanni, Jon E. Chatterton, Steven T. Miller |
2017-09-19 |
$6,611,000 |
| 9745585 |
RNAi-mediated inhibition of histamine receptor H1-related conditions |
John M. Yanni, Jon E. Chatterton, Steven T. Miller |
2017-08-29 |
$5,110,000 |
| 9533053 |
High concentration olopatadine ophthalmic composition |
Laman Alani, Malay Ghosh, Francisco Javier Galan, Nuria Carreras Perdiguer, Onkar N. Singh |
2017-01-03 |
|
| 9453220 |
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders |
John M. Yanni, John E. Chatterton, Steven T. Miller |
2016-09-27 |
$3,576,000 |
| 9447419 |
RNAi-mediated inhibition of tumor necrosis factor α-related conditions |
John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Steven T. Miller |
2016-09-20 |
$7,077,000 |
| 9371529 |
RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions |
John M. Yanni, Jon E. Chatterton, Steven T. Miller |
2016-06-21 |
$5,026,000 |
| 9206428 |
RNAi-mediated inhibition of histamine receptor H1-related conditions |
John M. Yanni, Jon E. Chatterton, Steven T. Miller |
2015-12-08 |
$5,606,000 |
| 8865671 |
RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions |
John M. Yanni, Jon E. Chatterton, Steven T. Miller |
2014-10-21 |
|
| 8791154 |
High concentration olopatadine ophthalmic composition |
Laman Alani, Malay Ghosh, Francisco Javier Galan, Nuria Carreras Perdiguer, Onkar N. Singh |
2014-07-29 |
|
| 8673873 |
RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders |
John M. Yanni, Jon E. Chatterton, Steven T. Miller |
2014-03-18 |
|
| 8618278 |
RNAi-mediated inhibition of histamine receptor H1-related conditions |
John M. Yanni, Jon E. Chatterton, Steven T. Miller |
2013-12-31 |
|
| 8541389 |
RNAi-mediated inhibition of tumor necrosis factor α-related conditions |
John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Steven T. Miller |
2013-09-24 |
|
| 8222227 |
RNAi-mediated inhibition of histamine receptor H1-related conditions |
John M. Yanni, Jon E. Chatterton, Steven T. Miller |
2012-07-17 |
|
| 8138205 |
Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 |
Steven P. Govek, Clay Beauregard, Mark R. Hellberg, Stewart A. Noble, Andrew K. Shiau +2 more |
2012-03-20 |
|
| 8048863 |
RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions |
John M. Yanni, Jon E. Chatterton, Steven T. Miller |
2011-11-01 |
|
| 8017592 |
RNAi-mediated inhibition of histamine receptor H1-related conditions |
John M. Yanni, Jon E. Chatterton, Steven T. Miller |
2011-09-13 |
|
| 7923471 |
Method of treating dry eye disorders and uveitis |
Peter G. Klimko, Mark R. Hellberg |
2011-04-12 |
|
| 7879905 |
5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses |
Peter G. Klimko, Mark R. Hellberg, David P. Bingaman |
2011-02-01 |
$36,923,000 |
| 7732421 |
RNAI-mediated inhibition of tumor necrosis factor α-related conditions |
John M. Yanni, Jon E. Chatterton, Diane Michelle Senchyna, Steven T. Miller |
2010-06-08 |
$101,661,000 |
| 7026296 |
Methods of treating dry eye disorders |
— |
2006-04-11 |
$106,671,000 |
| 6872382 |
Use of selective PDE IV inhibitors to treat dry eye disorders |
John M. Yanni |
2005-03-29 |
$67,827,000 |
| 6825232 |
Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders |
— |
2004-11-30 |
$77,870,000 |
| 6696453 |
Use of NF-&kgr;B inhibitors to treat dry eye disorders |
John M. Yanni |
2004-02-24 |
$37,157,000 |
| 6645978 |
Lipoxin A4 and its analogs for the treatment of dry eye |
Gustav Graff, Mark R. Hellberg, Peter G. Klimko, John M. Yanni |
2003-11-11 |
$29,930,000 |